Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing, “The Need to Make Insulin Affordable for All Americans,”
Unlocking an Affordable Future: Key #3 Support and Equip Clinicians ENHANCE PATIENT OUTCOMES AND IMPROVE THE PATIENT EXPERIENCE At the core of the pharmacy benefit specialty function lies expertise used to ensure the right patient gets the right drug in
In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress considers passing misguided proposals in the new year that will undermine the critical flexibility and
In case you missed it, last week’s RealClearPolitics’ virtual event, “The Consequences of Targeting Pharmacy Benefits,” featured policymakers and expert voices exploring the potential negative impact of policies being considered by Congress that target pharmacy benefit companies and market-based incentives
Pharmacy benefit companies negotiate rebates from drug companies, which they pass to health plan sponsors. Health plan sponsors then use the rebates to make pharmacy benefits more affordable for patients.
A wide array of voices from across the country are calling on lawmakers to oppose recently reintroduced legislation, the Pharmacy Benefit Manager Transparency Act (S.127), which fundamentally misconstrues the role of pharmacy benefit companies, unfairly proposes to take away employers’
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. All that Glitters is Not Gold… It’s true,
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. WHAT IS WHITE BAGGING… There’s a lot of jargon in
Bass Explains Opposition to Legislation, Risk of Drug Companies Lowering Rx Discounts On Wednesday, expert witnesses testifying before the U.S. House Committee on Energy & Commerce Subcommittee on Health highlighted the critical value pharmacy benefit companies provide for patients, employers, and
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the role of pharmacy benefit companies in the prescription drug supply chain in a new Forbes
©2024 PCMA. All Rights Reserved.
